Revenue
164 million USD
2026 Q2 · USD
Exact inputs and evidence
- Revenue: 163580000 USD Source
Fundies. English
OPKO Health, Inc.
EDGARAnnual consolidated revenue for 2025: about USD 606.9M, using the latest reported figures. The previous period, 2024, was about USD 713.1M.
Latest quarter
Operating margin
-4.26%
2026 Q2 · %
Operating cash flow
-43.5 million USD
2026 Q2 · USD
- Cash and cash equivalents
- 301 million USD Source
Exact value
300761000 USD
- Long-term debt including current maturities
- 349 million USD Source
Exact value
349050000 USD
- Shares outstanding
- Not available
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Revenue
588 million USD
2025-07-01 – 2026-06-30
Net income
-72.9 million USD
2025-07-01 – 2026-06-30
Operating cash flow
-123 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -152621000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -117974000 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -178542000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -152621000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -19310000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -62810000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -19310000 USD · 2026-01-01 – 2026-03-31 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-15.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 11 of 11 periods available· newest 2025-12-31
- Operating income: 11 of 11 periods available· newest 2025-12-31
- Net income: 11 of 11 periods available· newest 2025-12-31
- Operating cash flow: 11 of 11 periods available· newest 2025-12-31
- capital expenditure: No compatible figures in this window
- Total assets: 11 of 11 periods available· newest 2025-12-31
- Total liabilities: 11 of 11 periods available· newest 2025-12-31
- Current assets: 11 of 11 periods available· newest 2025-12-31
- Current liabilities: 11 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
- Long-term debt including current maturities: 7 of 11 periods available· newest 2025-12-31
- shares outstanding: No compatible figures in this window
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Revenue
-14.9%Prior period
USD 713.14 million
–
Current period
USD 606.88 million
–
Exact inputs and evidence
606879000 − 713142000 = -106263000 USD
713142000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source606879000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 172.46 millionPrior period
−USD 53.22 million
–
Current period
−USD 225.68 million
–
Exact inputs and evidence
-225680000 − -53224000 = -172456000 USD
-53224000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-225680000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 4.95 millionPrior period
−USD 183.49 million
–
Current period
−USD 178.54 million
–
Exact inputs and evidence
-178542000 − -183489000 = 4947000 USD
-183489000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-178542000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2025 2025-01-01 – 2025-12-31
- Revenue USD 606.88 million 100% of revenue
- Operating costs Derived USD 724.29 million 119% of revenue
- Operating income −USD 117.41 million −19% of revenue
- Tax, interest and other Derived USD 108.27 million 18% of revenue
- Net income −USD 225.68 million −37% of revenue
Cash
- Operating cash flow −USD 178.54 million −29% of revenue
- Capital expenditure Unavailable An input is unavailable.
- Free cash flow Derived Unavailable An input is unavailable.
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2016 Operating loss: operating costs were 109% of revenue.
- 2017 Operating loss: operating costs were 129% of revenue.
- 2018 Operating loss: operating costs were 117% of revenue.
- 2019 Operating loss: operating costs were 130% of revenue.
- 2020 96%
- 2021 Net loss: net income was −1.7% of revenue.
- 2022 Operating loss: operating costs were 123% of revenue.
- 2023 Operating loss: operating costs were 118% of revenue.
- 2024 Operating loss: operating costs were 121% of revenue.
- 2025 Operating loss: operating costs were 119% of revenue.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2016 2016-01-01 – 2016-12-31 | 1117494000 | 1214045000 Derived | -96551000 | -48192000 Derived | -48359000 | Unavailable | Source
|
| 2017 2017-01-01 – 2017-12-31 | 966006000 | 1242448000 Derived | -276442000 | 28808000 Derived | -305250000 | Unavailable | Source
|
| 2018 2018-01-01 – 2018-12-31 | 990266000 | 1161463000 Derived | -171197000 | -18157000 Derived | -153040000 | Unavailable | Source
|
| 2019 2019-01-01 – 2019-12-31 | 901935000 | 1175987000 Derived | -274052000 | 40873000 Derived | -314925000 | Unavailable | Source
|
| 2020 2020-01-01 – 2020-12-31 | 1435413000 | 1377699000 Derived | 57714000 | 27128000 Derived | 30586000 | Unavailable | Source
|
| 2021 2021-01-01 – 2021-12-31 | 1774718000 | 1755968000 Derived | 18750000 | 48893000 Derived | -30143000 | Unavailable | Source
|
| 2022 2022-01-01 – 2022-12-31 | 1004196000 | 1230449000 Derived | -226253000 | 102152000 Derived | -328405000 | Unavailable | Source
|
| 2023 2023-01-01 – 2023-12-31 | 863495000 | 1020516000 Derived | -157021000 | 31842000 Derived | -188863000 | Unavailable | Source
|
| 2024 2024-01-01 – 2024-12-31 | 713142000 | 865207000 Derived | -152065000 | -98841000 Derived | -53224000 | Unavailable | Source
|
| 2025 2025-01-01 – 2025-12-31 | 606879000 | 724288000 Derived | -117409000 | 108271000 Derived | -225680000 | Unavailable | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 606.9M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2016 | Revenue | 1117494000 |
|
| 2017 | Revenue | 966006000 |
|
| 2018 | Revenue | 990266000 |
|
| 2019 | Revenue | 901935000 |
|
| 2020 | Revenue | 1435413000 |
|
| 2021 | Revenue | 1774718000 |
|
| 2022 | Revenue | 1004196000 |
|
| 2023 | Revenue | 863495000 |
|
| 2024 | Revenue | 713142000 |
|
| 2025 | Revenue | 606879000 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
-14.9% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016 | Year over year | 149.7% |
|
| 2017 | Year over year | -13.6% |
|
| 2018 | Year over year | 2.5% |
|
| 2019 | Year over year | -8.9% |
|
| 2020 | Year over year | 59.1% |
|
| 2021 | Year over year | 23.6% |
|
| 2022 | Year over year | -43.4% |
|
| 2023 | Year over year | -14% |
|
| 2024 | Year over year | -17.4% |
|
| 2025 | Year over year | -14.9% |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin -19.3% 2025
Net margin -37.2% 2025
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016 | Operating margin | -8.6% |
|
| 2017 | Operating margin | -28.6% |
|
| 2018 | Operating margin | -17.3% |
|
| 2019 | Operating margin | -30.4% |
|
| 2020 | Operating margin | 4% |
|
| 2021 | Operating margin | 1.1% |
|
| 2022 | Operating margin | -22.5% |
|
| 2023 | Operating margin | -18.2% |
|
| 2024 | Operating margin | -21.3% |
|
| 2025 | Operating margin | -19.3% |
|
| 2016 | Net margin | -4.3% |
|
| 2017 | Net margin | -31.6% |
|
| 2018 | Net margin | -15.5% |
|
| 2019 | Net margin | -34.9% |
|
| 2020 | Net margin | 2.1% |
|
| 2021 | Net margin | -1.7% |
|
| 2022 | Net margin | -32.7% |
|
| 2023 | Net margin | -21.9% |
|
| 2024 | Net margin | -7.5% |
|
| 2025 | Net margin | -37.2% |
|
| 2016 | Free cash flow margin | Not reported |
|
| 2017 | Free cash flow margin | Not reported |
|
| 2018 | Free cash flow margin | Not reported |
|
| 2019 | Free cash flow margin | Not reported |
|
| 2020 | Free cash flow margin | Not reported |
|
| 2021 | Free cash flow margin | Not reported |
|
| 2022 | Free cash flow margin | Not reported |
|
| 2023 | Free cash flow margin | Not reported |
|
| 2024 | Free cash flow margin | Not reported |
|
| 2025 | Free cash flow margin | Not reported |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD -178.5M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2016 | Operating cash flow | 32046000 |
|
| 2017 | Operating cash flow | -92080000 |
|
| 2018 | Operating cash flow | -109141000 |
|
| 2019 | Operating cash flow | -172522000 |
|
| 2020 | Operating cash flow | 39476000 |
|
| 2021 | Operating cash flow | 38337000 |
|
| 2022 | Operating cash flow | -95189000 |
|
| 2023 | Operating cash flow | -28197000 |
|
| 2024 | Operating cash flow | -183489000 |
|
| 2025 | Operating cash flow | -178542000 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2016 | Free cash flow | Unavailable |
|
| 2017 | Free cash flow | Unavailable |
|
| 2018 | Free cash flow | Unavailable |
|
| 2019 | Free cash flow | Unavailable |
|
| 2020 | Free cash flow | Unavailable |
|
| 2021 | Free cash flow | Unavailable |
|
| 2022 | Free cash flow | Unavailable |
|
| 2023 | Free cash flow | Unavailable |
|
| 2024 | Free cash flow | Unavailable |
|
| 2025 | Free cash flow | Unavailable |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
34.4% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016 | Liabilities / assets | 26% |
|
| 2017 | Liabilities / assets | 28.8% |
|
| 2018 | Liabilities / assets | 26.9% |
|
| 2019 | Liabilities / assets | 30.1% |
|
| 2020 | Liabilities / assets | 32.4% |
|
| 2021 | Liabilities / assets | 29.8% |
|
| 2022 | Liabilities / assets | 27.9% |
|
| 2023 | Liabilities / assets | 30.9% |
|
| 2024 | Liabilities / assets | 37.9% |
|
| 2025 | Liabilities / assets | 34.4% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
3.97× 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016 | Current assets / current liabilities | 2.01× |
|
| 2017 | Current assets / current liabilities | 1.12× |
|
| 2018 | Current assets / current liabilities | 1.1× |
|
| 2019 | Current assets / current liabilities | 1.3× |
|
| 2020 | Current assets / current liabilities | 1.39× |
|
| 2021 | Current assets / current liabilities | 2.49× |
|
| 2022 | Current assets / current liabilities | 1.85× |
|
| 2023 | Current assets / current liabilities | 1.55× |
|
| 2024 | Current assets / current liabilities | 3.43× |
|
| 2025 | Current assets / current liabilities | 3.97× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2016 2016-01-01 – 2016-12-31 | −USD 48.36 million Exact valueExact value: -48359000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 32.05 million Exact valueExact value: 32046000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2017 2017-01-01 – 2017-12-31 | −USD 305.25 million Exact valueExact value: -305250000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 92.08 million Exact valueExact value: -92080000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2018 2018-01-01 – 2018-12-31 | −USD 153.04 million Exact valueExact value: -153040000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 109.14 million Exact valueExact value: -109141000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2019 2019-01-01 – 2019-12-31 | −USD 314.93 million Exact valueExact value: -314925000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 172.52 million Exact valueExact value: -172522000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2020 2020-01-01 – 2020-12-31 | USD 30.59 million Exact valueExact value: 30586000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 39.48 million Exact valueExact value: 39476000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2021 2021-01-01 – 2021-12-31 | −USD 30.14 million Exact valueExact value: -30143000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 38.34 million Exact valueExact value: 38337000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2022 2022-01-01 – 2022-12-31 | −USD 328.41 million Exact valueExact value: -328405000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 95.19 million Exact valueExact value: -95189000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2023-01-01 – 2023-12-31 | −USD 188.86 million Exact valueExact value: -188863000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 28.2 million Exact valueExact value: -28197000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | −USD 53.22 million Exact valueExact value: -53224000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 183.49 million Exact valueExact value: -183489000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −USD 225.68 million Exact valueExact value: -225680000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 178.54 million Exact valueExact value: -178542000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
210 filings · 7,504 latest values · 7,504 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0000944809, 944809, OPK, edgar:944809
Also known as CYTOCLONAL PHARMACEUTICS INC /DE, EXEGENICS INC, OPKO HEALTH, INC., OPKO Health, Inc., Opko Health, Inc., eXegenics Inc